Bioventure Leads Series A+ Round In Antiviral Drugs Maker Ark Biosciences

Pan Yue
February 6, 2017 — 14:13 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Australia Bioventure China chinese healthcare investment Morningside venture captial Oriza Oriza capital pharmaceutical qiming Qiming Venture Partners Shanghai Suzhou venture capital

Related News:

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Reports Indicate NVIDIA Tailoring Specialized Chips for China’s Market

November 9, 2023 — 23:26

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

ByteDance Invested In 52 Deals With Total Deal Value Of $6.4B: TikTok Parent Company’s Investments, M&A, Strategic Deals In One Chart 2019-2022

April 29, 2022 — 01:44

China’s Venture Mega-Deals 2019 to 2022 In One Chart: Can It Last?

April 15, 2022 — 00:30

Tencent Was Involved In 77 Investments Worth $11.9 Billion From 2021 To 2022 YTD; We Have It All In This One List

March 28, 2022 — 23:58